Delagoge et al. [65], Chappuis et al. [66], Warner et al. [67], Hubert et al. [68], Fourquet et al. [69] and Byrski et al. [70] provided evidence for remarkable sensitivity of BRCA1/2-related cancers to the neoadjuvant anthracycline-containing regimens. The gene discussed is BRCA1; the disease is cancer.